A Case Report of Successful Kidney Transplantation in a Patient With Chronic Myelogenous Leukemia (CML) Who Has Been in Remission for 15 Years on Imatinib
Transplantation Proceedings · 2023
DOI: 10.1016/j.transproceed.2023.03.058 ↗Kurz gefasst
Fallbericht in der Zeitschrift Transplantation Proceedings, 2023. Verfasst von Tadahiko Tokumoto und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan. Electronic address: tokumoto@dokkyomed.ac.jp. Hauptthemen laut MEDLINE: Kidney Transplantation, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Renal Insufficiency, Chronic, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 9 Literaturangaben.
Abstract (Originalsprache)
For chronic myeloid leukemia (CML), a Philadelphia chromosome-positive myeloproliferative neoplasm, the introduction of tyrosine kinase inhibitors has transformed CML from a lethal disease into a manageable chronic disease with a close-to-normal life expectancy. Active malignancy is an absolute contraindication to kidney transplantation. However, it is controversial whether kidney transplantation can be safely performed in patients with a history of CML who are in remission. We describe the clinical course of a 64-year-old male patient with chronic kidney disease from diabetic nephropathy (DMN) who underwent living donor kidney transplantation. The patient was diagnosed with CML 15 years ago and promptly achieved cytogenetic and molecular biological remission after starting imatinib. After that, he continued imatinib treatment for 15 years and was in remission, but his chronic kidney disease from DMN gradually worsened. A preemptive living donor kidney transplant was performed in July 2020. Imatinib for CML was discontinued because the patient maintained deep molecular remission (DMR) of major molecular response for more than 15 years before kidney transplantation. After kidney transplantation, the transplanted kidney function remained good at approximate serum creatinine levels of 1.1 mg/dL without histopathologic rejection, and the 3 monthly BCR-ABL1 measurement results were negative and are in progress. Thus, he continues to maintain treatment-free remission status without imatinib for 26 months after renal transplantation. In conclusion, this result suggests that CML with long-lasting DMR on imatinib therapy can be considered an inactive malignancy and therefore a relative indication for kidney transplantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan. Electronic address: tokumoto@dokkyomed.ac.jp.
- Department of Urology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
Zitieren
APA
Tokumoto, T., Setoguchi, K., Osaka, A., Ikezoe, E., Tsujioka, H., Hasegawa, K., Inoue, M., Nirazuka, A., Iwahata, T., Inoue, Y., & Saito, K. (2023). A Case Report of Successful Kidney Transplantation in a Patient With Chronic Myelogenous Leukemia (CML) Who Has Been in Remission for 15 Years on Imatinib. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2023.03.058
Vancouver
Tokumoto T, Setoguchi K, Osaka A, Ikezoe E, Tsujioka H, Hasegawa K, et al. A Case Report of Successful Kidney Transplantation in a Patient With Chronic Myelogenous Leukemia (CML) Who Has Been in Remission for 15 Years on Imatinib. Transplantation Proceedings. 2023. doi:10.1016/j.transproceed.2023.03.058
BibTeX
@article{Tokumoto2023,
author = {Tokumoto, Tadahiko and Setoguchi, Kiyoshi and Osaka, Akiyoshi and Ikezoe, Erika and Tsujioka, Hiroki and Hasegawa, Kintaro and Inoue, Minoru and Nirazuka, Asumi and Iwahata, Toshiyuki and Inoue, Yasuyuki and Saito, Kazutaka},
title = {A Case Report of Successful Kidney Transplantation in a Patient With Chronic Myelogenous Leukemia (CML) Who Has Been in Remission for 15 Years on Imatinib},
journal = {Transplantation Proceedings},
year = {2023},
doi = {10.1016/j.transproceed.2023.03.058}
}
EUVIMED